查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2000473

微量殘存疾病（MRD）液態生物檢體市場預測至2034年－按產品類型、癌症類型、檢體類型、技術、最終用戶和地區分類的全球分析

Minimal Residual Disease Liquid Biopsy Market Forecasts to 2034 - Global Analysis By Product, By Cancer Type, By Sample Type, By Technology, By End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球微量殘存疾病(MRD)液態生物檢體市場將達到 19 億美元，並在預測期內以 12% 的複合年成長率成長，到 2034 年達到 47 億美元。

微量殘存疾病（MRD）液態生物檢體是一種高靈敏度的診斷檢測方法，可檢測治療後患者體內殘留的少量癌細胞。這些檢測透過分析血液樣本中的循環腫瘤DNA（ctDNA）、循環性腫瘤細胞或其他生物標記物，來識別復發的早期徵兆。檢測MRD有助於臨床醫師監測治療效果、調整治療方法，並比傳統影像學方法更早發現復發。作為一種非侵入性診斷工具，MRD液態生物檢體支持個體化癌症治療，能夠更精準地監測疾病進展，並改善癌症的長期管理。

全球癌症發生率正在上升。

隨著癌症發病率持續上升，人們對能夠早期檢測疾病復發的先進診斷工具的需求日益成長。液態生物檢體技術能夠檢測治療後體內殘留的少量癌細胞。這些檢測方法為監測治療反應和疾病進展提供了一種非侵入性且高度靈敏的手段。醫療專業人員正擴大採用MRD檢測，以期透過早期療育改善患者預後。隨著腫瘤診斷技術的不斷發展，MRD液態生物檢體解決方案的需求預計將顯著成長。

某些癌症類型缺乏臨床檢驗

儘管微小殘留病灶（MRD）檢測已在白血病等骨髓惡性腫瘤中展現出較高的臨床效用，但其在某些固體癌中的有效性仍在研究中。缺乏針對多種癌症類型的標準化檢測通訊協定和檢驗研究可能會阻礙其在臨床實踐中的廣泛應用。醫療專業人員通常會在將新的診斷技術納入常規診療流程之前尋求可靠的臨床證據。此外，臨床數據不足可能會延遲監管部門的核准。這些挑戰可能會減緩MRD液態生物檢體技術的廣泛應用。

與精準醫療方法結合

精準醫療專注於根據患者的基因和分子特徵最佳化治療方案。微小殘留疾病（MRD）檢測可提供寶貴的分子訊息，幫助臨床醫生評估治療效果並預測復發風險。這些資訊可指導制定個人化治療策略和選擇標靶治療。製藥公司也將MRD生物標記納入臨床試驗，以評估新型癌症治療方法的療效。隨著個人化腫瘤學的不斷發展，MRD液態生物檢體技術在精準醫療中的作用預計將顯著增強。

與傳統切片檢查方法的競爭

傳統組織切片檢查在癌症診斷和後續觀察中仍然廣泛應用。許多醫療專業人員仍然依賴成熟的切片檢查技術，因為這些技術擁有悠久的臨床檢驗歷史。在某些情況下，組織切片檢查能夠提供關於腫瘤結構和特徵的更詳細資訊。此外，微小殘留病灶（MRD）液態生物檢體的成本和可近性可能會限制其在某些醫療機構中的應用。這些因素為液態生物檢體技術在腫瘤診斷的應用帶來了競爭挑戰。

新冠疫情的影響：

新冠疫情對微量殘存疾病（MRD）液態生物檢體市場產生了重大影響。疫情初期，醫療系統的中斷導致許多癌症篩檢和診斷程序延誤，與腫瘤診斷相關的臨床試驗也一度停滯。然而，疫情也促使人們對能夠減少病患就醫次數和感染風險的非侵入性診斷技術產生了濃厚的興趣。 MRD液態生物檢體僅需少量血液樣本，因此作為更安全、更便捷的監測工具而備受關注。隨著醫療系統的復甦，對先進癌症診斷技術的投資也隨之恢復。

在預測期內，白血病細分市場預計將佔據最大的市場佔有率。

鑑於微小殘留病灶（MRD）檢測在血液系統惡性腫瘤中具有很高的臨床療效，預計在預測期內，白血病領域將佔據最大的市場佔有率。白血病患者通常需要持續監測，以檢測治療後復發的可能性。 MRD液態生物檢體技術使臨床醫生能夠識別治療後血液中殘留的微量癌細胞。早期發現殘留病灶有助於及時調整治療方案，進而改善患者預後。醫療專業人員越來越依賴MRD檢測來進行白血病病例的風險分層和治療計劃制定。

在預測期內，製藥公司板塊預計將呈現最高的複合年成長率。

在預測期內，受藥物研發和臨床試驗中微小殘留疾病（MRD）生物標記應用日益廣泛推動，製藥公司板塊預計將呈現最高成長率。製藥公司正利用MRD檢測來評估新型癌症治療方法的有效性。 MRD數據能夠提供治療反應的早期指標，有助於加速臨床試驗的進程。隨著標靶治療和免疫療法的日益普及，分子診斷的重要性也進一步提升。在此領域，診斷公司與製藥廠商之間的合作也不斷拓展。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其強大的研究基礎設施和先進的醫療保健系統。該地區在腫瘤學領域對創新診斷技術的接受度很高。領先的生物技術公司和診斷實驗室正在該地區積極開發微小殘留病灶（MRD）液態生物檢體解決方案。政府對癌症研究的資助和監管支持也促進了市場成長。此外，癌症發生率的上升和精準醫療意識的增強也推動了MRD診斷技術的應用。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於癌症發生率的上升和醫療基礎設施的不斷改善。中國、日本、韓國和印度等國家正在大力投資先進的癌症診斷和研究計畫。分子診斷技術的日益普及正在提升該地區的癌症檢測和監測能力。此外，不斷成長的醫療支出和政府對精準醫療的支持措施也推動了市場擴張。全部區域增加。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對主要企業進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要企業市佔率分析
  • 產品基準評效和效能比較

第5章：全球微量殘存疾病（MRD）液態生物檢體市場：依產品分類

  • 基於NGS的微小殘留疾病（MRD）檢測
  • 基於PCR的微小殘留病灶檢測
  • 數位PCR MRD檢測
  • 無細胞DNA微小殘留疾病檢測
  • 其他產品

第6章：全球微量殘存疾病（MRD）液態生物檢體市場：依癌症類型分類

  • 骨髓惡性腫瘤
  • 白血病
  • 淋巴瘤
  • 多發性骨髓瘤
  • 固體癌
  • 其他癌症

第7章 全球微量殘存疾病（MRD）液態生物檢體市場：依樣本類型分類

  • 血
  • 骨髓
  • 電漿
  • 血清
  • 其他檢體類型

第8章：全球微量殘存疾病（MRD）液態生物檢體市場：依技術分類

  • 次世代定序（NGS）
  • 即時PCR
  • 數位液滴PCR
  • 光束技術
  • 流式細胞技術
  • 其他技術

第9章：全球微量殘存疾病（MRD）液態生物檢體市場：按最終用戶分類

  • 醫院
  • 腫瘤診所
  • 診斷檢查室
  • 學術研究機構
  • 製藥公司
  • 其他最終用戶

第10章：全球微量殘存疾病（MRD）液態生物檢體市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • Natera, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Guardant Health, Inc.
  • Adaptive Biotechnologies Corporation
  • IQVIA Holdings Inc.
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • Invitae Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • ArcherDx, Inc.
  • NeoGenomics Laboratories
  • Exact Sciences Corporation
  • GRAIL, LLC
  • BGI Genomics
Product Code: SMRC34508

According to Stratistics MRC, the Global Minimal Residual Disease (MRD) Liquid Biopsy Market is accounted for $1.9 billion in 2026 and is expected to reach $4.7 billion by 2034 growing at a CAGR of 12% during the forecast period. Minimal Residual Disease (MRD) Liquid Biopsy refers to highly sensitive diagnostic tests that detect small numbers of remaining cancer cells in a patient's body after treatment. These tests analyze circulating tumor DNA (ctDNA), circulating tumor cells, or other biomarkers in blood samples to identify early signs of relapse. MRD detection allows clinicians to monitor treatment effectiveness, adjust therapies, and detect recurrence earlier than conventional imaging methods. As a non-invasive diagnostic tool, MRD liquid biopsy supports personalized oncology care, enabling more precise disease monitoring and improved long-term cancer management.

Market Dynamics:

Driver:

Increasing cancer prevalence worldwide

As cancer incidence continues to rise, there is a growing need for advanced diagnostic tools that can detect disease recurrence at very early stages. MRD liquid biopsy technologies enable the detection of small amounts of cancer cells remaining in the body after treatment. These tests provide a non-invasive and highly sensitive method for monitoring treatment response and disease progression. Healthcare providers are increasingly adopting MRD testing to improve patient outcomes through early intervention. As oncology diagnostics evolve, the demand for MRD liquid biopsy solutions is expected to grow significantly.

Restraint:

Limited clinical validation in some cancers

Although MRD testing has demonstrated strong clinical utility in hematological malignancies such as leukemia, its effectiveness in some solid tumors is still under investigation. The lack of standardized testing protocols and validation studies across multiple cancer types can limit broader clinical adoption. Healthcare providers often require strong clinical evidence before incorporating new diagnostic technologies into routine practice. Additionally, regulatory approvals can be delayed when sufficient clinical data is unavailable. These challenges may slow the widespread implementation of MRD liquid biopsy technologies.

Opportunity:

Integration with precision medicine approaches

Precision medicine focuses on tailoring treatments based on a patient's genetic and molecular profile. MRD testing provides valuable molecular insights that help clinicians determine treatment effectiveness and identify potential relapse. This information can guide personalized treatment decisions and targeted therapy selection. Pharmaceutical companies are also incorporating MRD biomarkers into clinical trials to evaluate the effectiveness of new cancer therapies. As personalized oncology continues to expand, the role of MRD liquid biopsy technologies in precision medicine is expected to increase substantially.

Threat:

Competition from traditional biopsy methods

Conventional tissue biopsies remain widely used for cancer diagnosis and monitoring. Many healthcare providers still rely on established biopsy techniques due to their long history of clinical validation. In some cases, tissue biopsies provide more detailed information about tumor structure and characteristics. Additionally, the cost and availability of MRD liquid biopsy tests may limit their adoption in certain healthcare settings. These factors create competitive pressure on the adoption of liquid biopsy technologies in oncology diagnostics.

Covid-19 Impact:

The COVID-19 pandemic had a notable impact on the Minimal Residual Disease Liquid Biopsy market. During the early stages of the pandemic, many cancer screening and diagnostic procedures were delayed due to healthcare system disruptions. Clinical trials related to oncology diagnostics also experienced temporary slowdowns. However, the pandemic increased interest in non-invasive diagnostic technologies that reduce hospital visits and patient exposure to infections. MRD liquid biopsy tests, which require simple blood samples, gained attention as a safer and more convenient monitoring tool. As healthcare systems recovered, investments in advanced cancer diagnostics resumed.

The leukemia segment is expected to be the largest during the forecast period

The leukemia segment is expected to account for the largest market share during the forecast period as MRD testing has shown strong clinical effectiveness in hematological cancers. Leukemia patients often require continuous monitoring after treatment to detect possible disease relapse. MRD liquid biopsy techniques allow clinicians to identify minimal cancer cells that remain in the bloodstream after therapy. Early detection of residual disease enables timely treatment adjustments and improved patient outcomes. Healthcare providers increasingly rely on MRD testing for risk stratification and treatment planning in leukemia cases.

The pharmaceutical companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pharmaceutical companies segment is predicted to witness the highest growth rate due to increasing use of MRD biomarkers in drug development and clinical trials. Pharmaceutical firms are utilizing MRD testing to evaluate the effectiveness of novel cancer therapies. MRD data can help accelerate clinical trial outcomes by providing early indicators of treatment response. The growing focus on targeted therapies and immunotherapies is further increasing the importance of molecular diagnostics. Collaborations between diagnostic companies and pharmaceutical manufacturers are also expanding in this area.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to strong research infrastructure and advanced healthcare systems. The region has a high adoption rate of innovative diagnostic technologies in oncology care. Leading biotechnology companies and diagnostic laboratories are actively developing MRD liquid biopsy solutions in this region. Government funding and regulatory support for cancer research also contribute to market growth. Additionally, the rising prevalence of cancer and growing awareness of precision medicine further support the adoption of MRD diagnostics.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by increasing cancer incidence and expanding healthcare infrastructure. Countries such as China, Japan, South Korea, and India are investing heavily in advanced cancer diagnostics and research programs. The growing adoption of molecular diagnostic technologies is improving cancer detection and monitoring capabilities in the region. Additionally, rising healthcare expenditure and government initiatives supporting precision medicine are encouraging market expansion. International collaborations and clinical research activities are also increasing across Asia Pacific.

Key players in the market

Some of the key players in Minimal Residual Disease (MRD) Liquid Biopsy Market include Natera, Inc., F. Hoffmann-La Roche Ltd., Guardant Health, Inc., Adaptive Biotechnologies Corporation, IQVIA Holdings Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Invitae Corporation, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., ArcherDx, Inc., NeoGenomics Laboratories, Exact Sciences Corporation, GRAIL, LLC and BGI Genomics.

Key Developments:

In January 2026, Natera and Exelixis announced a collaboration on the STELLAR-316 trial, a randomized Phase 3 study that will use Natera's Signatera test to identify MRD-positive patients with resected Stage II/III colorectal cancer for evaluation of the drug zanzalintinib.

In April 2025, Guardant Health announced an agreement with Bayshore HealthCare to offer its precision oncology tests through Bayshore's network of clinics in Canada . This partnership will provide Canadian patients with access to the Guardant Reveal(TM) blood test for MRD detection and recurrence monitoring in early-stage cancer.

Products Covered:

  • NGS-Based MRD Assays
  • PCR-Based MRD Assays
  • Digital PCR MRD Tests
  • Cell-Free DNA MRD Tests
  • Other Products

Cancer Types Covered:

  • Hematological Malignancies
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Solid Tumors
  • Other Cancer Types

Sample Types Covered:

  • Blood
  • Bone Marrow
  • Plasma
  • Serum
  • Other Sample Types

Technologies Covered:

  • Next-Generation Sequencing (NGS)
  • Real-Time PCR
  • Digital Droplet PCR
  • BEAMing Technology
  • Flow Cytometry
  • Other Technologies

End Users Covered:

  • Hospitals
  • Oncology Clinics
  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Pharmaceutical Companies
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Product

  • 5.1 NGS-Based MRD Assays
  • 5.2 PCR-Based MRD Assays
  • 5.3 Digital PCR MRD Tests
  • 5.4 Cell-Free DNA MRD Tests
  • 5.5 Other Products

6 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Cancer Type

  • 6.1 Hematological Malignancies
  • 6.2 Leukemia
  • 6.3 Lymphoma
  • 6.4 Multiple Myeloma
  • 6.5 Solid Tumors
  • 6.6 Other Cancer Types

7 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Sample Type

  • 7.1 Blood
  • 7.2 Bone Marrow
  • 7.3 Plasma
  • 7.4 Serum
  • 7.5 Other Sample Types

8 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Technology

  • 8.1 Next-Generation Sequencing (NGS)
  • 8.2 Real-Time PCR
  • 8.3 Digital Droplet PCR
  • 8.4 BEAMing Technology
  • 8.5 Flow Cytometry
  • 8.6 Other Technologies

9 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By End User

  • 9.1 Hospitals
  • 9.2 Oncology Clinics
  • 9.3 Diagnostic Laboratories
  • 9.4 Academic & Research Institutes
  • 9.5 Pharmaceutical Companies
  • 9.6 Other End Users

10 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Natera, Inc.
  • 13.2 F. Hoffmann-La Roche Ltd.
  • 13.3 Guardant Health, Inc.
  • 13.4 Adaptive Biotechnologies Corporation
  • 13.5 IQVIA Holdings Inc.
  • 13.6 Illumina, Inc.
  • 13.7 Thermo Fisher Scientific Inc.
  • 13.8 Invitae Corporation
  • 13.9 Agilent Technologies, Inc.
  • 13.10 Bio-Rad Laboratories, Inc.
  • 13.11 ArcherDx, Inc.
  • 13.12 NeoGenomics Laboratories
  • 13.13 Exact Sciences Corporation
  • 13.14 GRAIL, LLC
  • 13.15 BGI Genomics

List of Tables

  • Table 1 Global Minimal Residual Disease (MRD) Liquid Biopsy Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Product (2023-2034) ($MN)
  • Table 3 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By NGS-Based MRD Assays (2023-2034) ($MN)
  • Table 4 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By PCR-Based MRD Assays (2023-2034) ($MN)
  • Table 5 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Digital PCR MRD Tests (2023-2034) ($MN)
  • Table 6 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Cell-Free DNA MRD Tests (2023-2034) ($MN)
  • Table 7 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Other Products (2023-2034) ($MN)
  • Table 8 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Cancer Type (2023-2034) ($MN)
  • Table 9 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Hematological Malignancies (2023-2034) ($MN)
  • Table 10 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Leukemia (2023-2034) ($MN)
  • Table 11 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Lymphoma (2023-2034) ($MN)
  • Table 12 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Multiple Myeloma (2023-2034) ($MN)
  • Table 13 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Solid Tumors (2023-2034) ($MN)
  • Table 14 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Other Cancer Types (2023-2034) ($MN)
  • Table 15 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Sample Type (2023-2034) ($MN)
  • Table 16 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Blood (2023-2034) ($MN)
  • Table 17 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Bone Marrow (2023-2034) ($MN)
  • Table 18 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Plasma (2023-2034) ($MN)
  • Table 19 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Serum (2023-2034) ($MN)
  • Table 20 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Other Sample Types (2023-2034) ($MN)
  • Table 21 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Technology (2023-2034) ($MN)
  • Table 22 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Next-Generation Sequencing (NGS) (2023-2034) ($MN)
  • Table 23 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Real-Time PCR (2023-2034) ($MN)
  • Table 24 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Digital Droplet PCR (2023-2034) ($MN)
  • Table 25 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By BEAMing Technology (2023-2034) ($MN)
  • Table 26 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Flow Cytometry (2023-2034) ($MN)
  • Table 27 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Other Technologies (2023-2034) ($MN)
  • Table 28 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By End User (2023-2034) ($MN)
  • Table 29 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Hospitals (2023-2034) ($MN)
  • Table 30 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Oncology Clinics (2023-2034) ($MN)
  • Table 31 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 32 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Academic & Research Institutes (2023-2034) ($MN)
  • Table 33 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Pharmaceutical Companies (2023-2034) ($MN)
  • Table 34 Global Minimal Residual Disease (MRD) Liquid Biopsy Market, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.